Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Immunol., 23 June 2025

Sec. Immunological Tolerance and Regulation

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1632381

Correction: Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology

This article is a correction to:

  1. Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology

    1. Read original article
Xinyao Zhou&#x;Xinyao Zhou1†Wuqian Wang,&#x;Wuqian Wang2,3†Luan ChenLuan Chen3Yingjun YangYingjun Yang4Xing WeiXing Wei1Jia ZhouJia Zhou1Kuan SunKuan Sun1Ping TangPing Tang5Xiaofang SunXiaofang Sun2Shengying Qin*Shengying Qin3*Luming Sun,*Luming Sun4,6*
  • 1Department of Fetal Medicine & Prenatal Diagnosis Center, Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China
  • 2Department of Obstetrics and Gynecology, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangdong-Hong Kong-Macao Greater Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, The Third Affiliated Hospital, Guangzhou Medical University, Guangzhou, China
  • 3Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China
  • 4Department of Obstetrics, Center of Fetal Medicine & Intrauterine Pediatrics, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • 5Jiaxing Maternity and Children Health Care Hospital, Affiliated Women and Children Hospital, Jiaxing University, Jiaxing, Zhejiang, China
  • 6School of Medicine, Tongji University, Shanghai, China

A Correction on
Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology

By Zhou X, Wang W, Chen L, Yang Y, Wei X, Zhou J, Sun K, Tang P, Sun X, Qin S and Sun L (2025). Front. Immunol. 16:1542034. doi: 10.3389/fimmu.2025.1542034

In the published article, there was an error in Figure 2B as published. Incorrect values were displayed on the pie chart. The corrected Figure 2 and its caption “Figure 2 Descriptive statistics of clinical information of FGR patients. (A) Gestational Week for Collection of Maternal Peripheral Blood for FGR patients and control samples; (B) Blood flow conditions for FGR patients; (C) Combined symptoms for FGR patients” appear below.

Figure 2
Panel A is a line graph showing gestational weeks for collecting maternal peripheral blood, comparing FGR and control groups. Panel B is a pie chart depicting blood flow conditions with four segments: mild abnormalities (37%), persistent absence (43%), reversed flow (9%), and intermittent absence (11%). Panel C is a bar chart displaying combined symptoms, highlighting conditions like preeclampsia and gestational diabetes mellitus with varying frequencies.

Figure 2. Descriptive statistics of clinical information of FGR patients. (A) Gestational Week for Collection of Maternal Peripheral Blood for FGR patients and control samples; (B) Blood flow conditions for FGR patients; (C) Combined symptoms for FGR patients.

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: fetal growth restriction (FGR), Olink proteomics platform, proximity extension assay (PEA), biomarkers, targeted proteomics analysis

Citation: Zhou X, Wang W, Chen L, Yang Y, Wei X, Zhou J, Sun K, Tang P, Sun X, Qin S and Sun L (2025) Correction: Investigation of potential protein biomarkers for the screening of placental-mediated fetal growth restriction disorders using targeted proteomics Olink technology. Front. Immunol. 16:1632381. doi: 10.3389/fimmu.2025.1632381

Received: 21 May 2025; Accepted: 05 June 2025;
Published: 23 June 2025.

Edited and Reviewed by:

David Cameron Wraith, University of Birmingham, United Kingdom

Copyright © 2025 Zhou, Wang, Chen, Yang, Wei, Zhou, Sun, Tang, Sun, Qin and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Shengying Qin, Y2hpbnNpckBzanR1LmVkdS5jbg==; Luming Sun, bHVtaW5nX3N1bkAxNjMuY29t

†These authors share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.